Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 165

The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.

T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study

Open access
Angyal, Adrienn, Longet, Stephanie, Moore, Shona C, Payne, Rebecca P, Harding, Adam, Tipton, Tom, Rongkard, Patpong, Ali, Mohammad, Hering, Luisa M, Meardon, Naomi, Austin, James, Brown, Rebecca, Skelly, Donal, Gillson, Natalie, Dobson, Sue L, Cross, Andrew, Sandhar, Gurjinder, Kilby, Jonathan A, Tyerman, Jessica K, Nicols, Alexander R, Spegarova, Jarmila S, Mehta, Hema, Hornsby, Hailey, Whitham, Rachel, Conlon, Christopher P, Jeffery, Katie, Goulder, Philip, Frater, John, Dold, Christina, Pace, Matthew, Ogbe, Ane, Brown, Helen, Ansari, M Azim, Adland, Emily, Brown, Anthony, Chand, Meera, Shields, Adrian, Matthews, Philippa C, Hopkins, Susan, Hall, Victoria, James, William, Rowland-Jones, Sarah L, Klenerman, Paul, Dunachie, Susanna, Richter, Alex, Duncan, Christopher J A, Barnes, Eleanor, Carroll, Miles, Turtle, Lance, de Silva, Thushan I, Harding, Adam, Watson, Adam, Shields, Adrian, Angyal, Adrienn, Alhussni, Ahmed, Richter, Alex, Nicols, Alexander, Deeks, Alexandra, Webb-Bridges, Alice, Cross, Andrew, Ogbe, Ane, Jämsén, Anni, Brown, Anthony, Chawla, Anu, Dold, Christina, Duncan, Christopher, Conlon, Christopher, Skelly, Donal, O'Donnell, Denise, Barnes, Eleanor, Adland, Emily, Weeks, Esme, Sandhar, Gurjinder, Hornsby, Hailey, Brown, Helen, Mehta, Hema, Abuelgasim, Hibatullah, Xiao, Huiyuan, Austin, James, Spegarova, Jarmila, Holmes, Jennifer, Haworth, Jenny, Tyerman, Jessica, Frater, John, Kilby, Jonathan, Cutteridge, Joseph, Jeffery, Katie, Lillie, Katy, Turtle, Lance, Romaniuk, Leigh, Denly, Lucy, Hering, Luisa, Ansari, M. Azim, Pace, Matthew, Chand, Meera, Carroll, Miles, Ali, Mohammad, Kasanyinga, Mwila, Meardon, Naomi, Gillson, Natalie, Rongkard, Patpong, Klenerman, Paul, Goulder, Philip, Matthews, Philippa, Whitham, Rachel, Brown, Rebecca, Payne, Rebecca, Wilson, Robert, Rowland-Jones, Sarah, Thomas, Sarah, Moore, Shona, Gardiner, Siobhan, Longet, Stephanie, Tucker, Stephanie, Dobson, Sue, Hopkins, Susan, Dunachie, Susanna, Adlou, Syed, de Silva, Thushan, Tipton, Tom, Hall, Victoria, James, William, Lawrie, Allan, Smith, Nikki, Turton, Helena, Zawia, Amira, Bayley, Martin, Fairman, Alex, Harrington, Kate, Kirk, Rosemary, Marsh, Louise, Watson, Lisa, Wood, Steven, Diffey, Benjamin, Jones, Chris, Lett, Lauren, Platt, Gareth, Subramaniam, Krishanthi, Wootton, Daniel, Payne, Brendan, Hambleton, Sophie, Kelly, Sinead, Marston, Judith, Poolan, Sonia, Turner, Dianne, Haniffa, Muzlifah, Stephenson, Emily, Adele, Sandra, Akhter, Hossain Delowar, Chinnakannan, Senthil, de Lara, Catherine, Donnison, Timothy, Hackstein, Carl-Philipp, Lee, Lian, Lim, Nicholas, Malone, Tom, Phillips, Eloise, Ramamurthy, Narayan, Robinson, Nichola, Sampson, Oliver, Eyre, David, Simmons, Beatrice, Stafford, Lizzie, Mentzer, Alexander, Amini, Ali, Arancibia-Cárcamo, Carolina, Provine, Nicholas, Travis, Simon, Dimitriadis, Stavros, Johnson, Sile, Foulkes, Sarah, Khawam, Jameel, Wellington, Edgar, Gilbert-Jaramillo, Javier, Knight, Michael, Dupont, Maeva, Horner, Emily, Thaventhiran, James, Chalk, Jeremy · 2022 · The Lancet Microbe

Abstract

Background Previous infection with SARS-CoV-2 affects the immune response to the first dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and antibody responses in health-care workers with and without previous SARS-CoV-2 infection following a single dose of the BNT162b2 (tozinameran; Pfizer–BioNTech) mRNA vaccine. Methods We sampled health-care workers enrolled in the PITCH study across four hospital sites in the UK (Oxford, Liverpool, Newcastle, and Sheffield). All health-care workers aged 18 years or older consenting to participate in this prospective cohort study were included, with no exclusion criteria applied. Blood samples were collected where possible before vaccination and 28 (±7) days following one or two doses (given 3–4 weeks apart) of the BNT162b2 vaccine. Previous infection was determined by a documented SARS-CoV-2-positive RT-PCR result or the presence of positive anti-SARS-CoV-2 nucleocapsid antibodies. We measured spike-specific IgG antibodies and quantified T-cell responses by interferon-γ enzyme-linked immunospot assay in all participants where samples were available at the time of analysis, comparing SARS-CoV-2-naive individuals to those with previous infection. Findings Between Dec 9, 2020, and Feb 9, 2021, 119 SARS-CoV-2-naive and 145 previously infected health-care workers received one dose, and 25 SARS-CoV-2-naive health-care workers received two doses, of the BNT162b2 vaccine. In previously infected health-care workers, the median time from previous infection to vaccination was 268 days (IQR 232–285). At 28 days (IQR 27–33) after a single dose, the spike-specific T-cell response measured in fresh peripheral blood mononuclear cells (PBMCs) was higher in previously infected (n=76) than in infection-naive (n=45) health-care workers (median 284 [IQR 150–461] vs 55 [IQR 24–132] spot-forming units [SFUs] per 10 6 PBMCs; p<0·0001). With cryopreserved PBMCs, the T-cell response in previously infected individuals (n=52) after one vaccine dose was equivalent to that of infection-naive individuals (n=19) after receiving two vaccine doses (median 152 [IQR 119–275] vs 162 [104–258] SFUs/10 6 PBMCs; p=1·00). Anti-spike IgG antibody responses following a single dose in 142 previously infected health-care workers (median 270 373 [IQR 203 461–535 188] antibody units [AU] per mL) were higher than in 111 infection-naive health-care workers following one dose (35 001 [17 099–55 341] AU/mL; p<0·0001) and higher than in 25 infection-naive individuals given two doses (180 904 [108 221–242 467] AU/mL; p<0·0001). Interpretation A single dose of the BNT162b2 vaccine is likely to provide greater protection against SARS-CoV-2 infection in individuals with previous SARS-CoV-2 infection, than in SARS-CoV-2-naive individuals, including against variants of concern. Future studies should determine the additional benefit of a second dose on the magnitude and durability of immune responses in individuals vaccinated following infection, alongside evaluation of the impact of extending the interval between vaccine doses. Funding UK Department of Health and Social Care, and UK Coronavirus Immunology Consortium.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s2666-5247(21)00275-5

Cites

18 of 18 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 18 references

Research works printed but not linked: 14

  1. Pritchard, 2021, Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom, Nat Med, 27, 1370, 10.1038/s41591-021-01410-w · DOI · Paper page
  2. Hall, 2021, Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020, medRxiv
  3. Skelly, 2021, Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern, Nat Commun, 12, 10.1038/s41467-021-25167-5 · doi:10.1038/s41467-021-25167-5
  4. Robertson, 2021, Delayed second dose of the BNT162b2 vaccine: innovation or misguided conjecture?, Lancet, 397, 879, 10.1016/S0140-6736(21)00455-4 · DOI
  5. Gobbi, 2021, Antibody response to the BNT162b2 mRNA COVID-19 vaccine in subjects with prior SARS-CoV-2 infection, Viruses, 13, 422, 10.3390/v13030422 · DOI · Paper page
  6. Ebinger, 2021, Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2, Nat Med, 27, 981, 10.1038/s41591-021-01325-6 · DOI · Paper page
  7. Demonbreun, 2021, Comparison of IgG and neutralizing antibody responses after one or two doses of COVID-19 mRNA vaccine in previously infected and uninfected individuals, EClinicalMedicine, 38, 10.1016/j.eclinm.2021.101018 · DOI
  8. Buonfrate, 2021, Antibody response induced by the BNT162b2 mRNA COVID-19 vaccine in a cohort of health-care workers, with or without prior SARS-CoV-2 infection: a prospective study, Clin Microbiol Infect, 10.1016/j.cmi.2021.07.024 · DOI
  9. Voysey, 2021, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, 397, 99, 10.1016/S0140-6736(20)32661-1 · DOI · Paper page
  10. Callaway, 2021, Fast-spreading COVID variant can elude immune responses, Nature, 589, 500, 10.1038/d41586-021-00121-z · DOI
  11. Claro, 2021, Local transmission of SARS-CoV-2 lineage B.1.1.7, Brazil, December 2020, Emerg Infect Dis, 27, 970, 10.3201/eid2703.210038 · DOI
  12. Zhou, 2021, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera, Cell, 184, 2348, 10.1016/j.cell.2021.02.037 · DOI · Paper page
  13. Lozano-Ojalvo, 2021, Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naive and COVID-19 recovered individuals, Cell Rep, 36, 10.1016/j.celrep.2021.109570 · DOI
  14. Tarke, 2021, Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals, Cell Rep Med, 2

Cited by

See all 165

Metadata

Authors
Angyal, A., Longet, S., Moore, S. C., Payne, R. P., Harding, A., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., Austin, J., Brown, R., Skelly, D., Gillson, N., Dobson, S. L., Cross, A., Sandhar, G., Kilby, J. A., Tyerman, J. K., Nicols, A. R., Spegarova, J. S., Mehta, H., Hornsby, H., Whitham, R., Conlon, C. P., Jeffery, K., Goulder, P., Frater, J., Dold, C., Pace, M., Ogbe, A., Brown, H., Ansari, M. A., Adland, E., Brown, A., Chand, M., Shields, A., Matthews, P. C., Hopkins, S., Hall, V., James, W., Rowland-Jones, S. L., Klenerman, P., Dunachie, S., Richter, A., Duncan, C. J. A., Barnes, E., Carroll, M., Turtle, L., de Silva, T. I., Harding, A., Watson, A., Shields, A., Angyal, A., Alhussni, A., Richter, A., Nicols, A., Deeks, A., Webb-Bridges, A., Cross, A., Ogbe, A., Jämsén, A., Brown, A., Chawla, A., Dold, C., Duncan, C., Conlon, C., Skelly, D., O'Donnell, D., Barnes, E., Adland, E., Weeks, E., Sandhar, G., Hornsby, H., Brown, H., Mehta, H., Abuelgasim, H., Xiao, H., Austin, J., Spegarova, J., Holmes, J., Haworth, J., Tyerman, J., Frater, J., Kilby, J., Cutteridge, J., Jeffery, K., Lillie, K., Turtle, L., Romaniuk, L., Denly, L., Hering, L., Ansari, M. A., Pace, M., Chand, M., Carroll, M., Ali, M., Kasanyinga, M., Meardon, N., Gillson, N., Rongkard, P., Klenerman, P., Goulder, P., Matthews, P., Whitham, R., Brown, R., Payne, R., Wilson, R., Rowland-Jones, S., Thomas, S., Moore, S., Gardiner, S., Longet, S., Tucker, S., Dobson, S., Hopkins, S., Dunachie, S., Adlou, S., de Silva, T., Tipton, T., Hall, V., James, W., Lawrie, A., Smith, N., Turton, H., Zawia, A., Bayley, M., Fairman, A., Harrington, K., Kirk, R., Marsh, L., Watson, L., Wood, S., Diffey, B., Jones, C., Lett, L., Platt, G., Subramaniam, K., Wootton, D., Payne, B., Hambleton, S., Kelly, S., Marston, J., Poolan, S., Turner, D., Haniffa, M., Stephenson, E., Adele, S., Akhter, H. D., Chinnakannan, S., de Lara, C., Donnison, T., Hackstein, C.-P., Lee, L., Lim, N., Malone, T., Phillips, E., Ramamurthy, N., Robinson, N., Sampson, O., Eyre, D., Simmons, B., Stafford, L., Mentzer, A., Amini, A., Arancibia-Cárcamo, C., Provine, N., Travis, S., Dimitriadis, S., Johnson, S., Foulkes, S., Khawam, J., Wellington, E., Gilbert-Jaramillo, J., Knight, M., Dupont, M., Horner, E., Thaventhiran, J., & Chalk, J.
Venue
The Lancet Microbe
Publisher
Elsevier BV
Published
2022-01
Volume
3
Issue
1
Pages
e21-e31
ISSN
2666-5247 (ISSN-L)
OpenAlex
W3211947794
Cited by
165
References
18
FWCI
10.96
Type
journal article
Language
en
Open access
gold
Licence
Funders
Wellcome Trust

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. https://app.cochat.ai/papers/10.1016/s2666-5247(21)00275-5
The paper
Angyal, A., Longet, S., Moore, S. C., Payne, R. P., Harding, A., Tipton, T., Rongkard, P., Ali, M., Hering, L. M., Meardon, N., Austin, J., Brown, R., Skelly, D., Gillson, N., Dobson, S. L., Cross, A., Sandhar, G., Kilby, J. A., Tyerman, J. K., . . . Chalk, J. (2022). T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. The Lancet Microbe. https://doi.org/10.1016/s2666-5247(21)00275-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.